malarial

Antimalarial agent 30 has anti-Plasmodium berghei liver stage parasite activity and antimalarial activity for the study of malarial infections.

Antimalarial agent 1 is an effective antimalarial agent.

Antimalarial agent 14 (NSC-102533) is a bioactive chemical.

Antimalarial agent 13 (N2-(3-chlorophenyl)-N4-(furan-2-ylmethyl)quinazoline-2,4-diamine) is a potent antimalarial agent.

Compound 42 (Compound 2), an antimalarial agent, effectively inhibits Plasmodium falciparum during the asexual blood stages (IC 50 <0.5μM) and gametocytes (IC 50 is 0.14 μM).

Antimalarial agent 43 (compound 16c) is an antimalarial compound that exhibits an IC50 value of 0.0151 μM against the 3D7 strain.

Antimalarial agent 45 (compound 8I) is an antimalarial with activity against Plasmodium parasites, exhibiting an IC50 of 0.21 μM. It is used in the study of malaria.

Antimalarial agent 44 (Compound 3) is an antiparasitic agent effective against malaria. It exhibits good permeability in MDCK-MDR1 cell monolayers and has a high clearance rate in mouse liver microsomes.

Antimalarial agent 46 (Compound 42a) is a compound with antimalarial activity, effective in inhibiting P. falciparum lines.

Antimalarial agent 47 (compound F14) is a chemical compound effective against Plasmodium falciparum, specifically targeting the W2 strain with an IC50 value of 235 nM.

Antimalarial agent 48 (Compound 15a) is a triazine compound with antimalarial activity, showing effectiveness against Plasmodium falciparum K1 and Plasmodium falciparum FCR3 with IC50 values of 280 and 290 nM, respectively. It holds promise for research in the field of anti-infective treatments.

Antimalarial agent 3, an antimalarial agent, exhibits potent activity against Plasmodium with an IC50 of 0.035 μM. Furthermore, it demonstrates an exceptionally high selectivity index in relation to mammalian cells.

Antimalarial agent 11 (compound 1), a spirocyclic chromane, is a potent antimalarial agent effective against D6 (EC50: 1.48 μM) and ARC08-022 (EC50: 1.81 μM).

Antimalarial agent 7 is a potent and effective inhibitor of PfATP4, showing potential for studying human Plasmodium falciparum.

Antimalarial agent 8 (Compound 7e) is a novel, orally active antimalarial effective against P. falciparum in vitro and in vivo in a mouse model of malaria at 40 mg kg.

Antimalarial agent 2 is an orally active, novel antimalarial agent that exhibits rapid in vitro killing effects.

Antimalarial agent 10 (Compound 17b) is an amino alcohol-quinoline compound. It exhibits antimalarial activity against Pf3D7 (IC50: 14.9 nM) and PfW2 (IC50: 11 nM) with a selectivity index greater than 770, irrespective of the cell line.

Antimalarial agent 15 is a parasite inhibitor that exhibits antimalarial effects and inhibits the growth of Plasmodium falciparum 3D7 with an IC50 value of 20 nM.

Antimalarial agent 12 is an effective antimalarial agent that inhibits the growth of Plasmodium falciparum strains Dd2 and 3D7 with EC50 values of 155 nM and 136 nM, respectively. antimalarial agent 12 has a MIC >250,000 nM against E. coli and also acts on Antimalarial agent 12 has a MIC of >250,000 nM against E. coli and also works on HEK-293 and hPHep cell lines with CC50 values of 10,000-50,000 nM.

Antimalarial agent 16 is a parasite inhibitor that exhibits antimalarial effects and inhibits the growth of Plasmodium falciparum with an IC50 value of 2.0 nM.

Antimalarial agent 9 is an effective antimalarial agent, a quinoline-imidazole derivative compound. antimalarial agent 9 showed significant in vitro antimalarial effects against CQ-susceptible strains (IC50-0.14 μM) and MDR strains (IC50-0.41 μM), with minimal cytotoxicity and high selectivity.

Antimalarial agent 20, exhibiting potent efficacy with an IC50 value of 0.6 nM against the P. falciparum NF54 parasite strain within the NF54 albumax assay, serves as a significant antimalarial compound.

Antimalarial agent 18, a powerful antimalarial compound characterized by its electronic, highly lipophilic, and siderophoric properties, falls within the acyloxymethyl series, acting as a fosmidomycin surrogate. It effectively inhibits the non-mevalonate isoprenoid biosynthesis pathway by targeting the IspC enzyme. This compound demonstrates significant inhibitory activity against P. falciparum (IC50 = 50 nM) and A. baumanii (IC50 = 390 nM).

Antimalarial agent 17, functioning both as an antimalarial agent and a herbicide, inhibits photosystem II and demonstrates post-emergence herbicidal efficacy comparable to commercial herbicides [1].